ScreenerHero

NAMSNewAmsterdam Pharma Company N.V. Ordinary Shares

NAS · US · Healthcare · Biotechnology · newamsterdampharma.com
27.87USD-2.31%Mkt Cap: 3.33B $P/E: —

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap3.33B $
Enterprise Value2.69B $
Revenue (TTM)7.12M $
Gross Profit7.12M $
Net Income (TTM)-203.82M $
Revenue/Share0.0590 USD
Last Price27.87 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees100
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-17.81
PEG—
EV/EBITDA-11.01
EV/Revenue377.33
P/S456.06
P/B5.18
EPS (TTM)-2.10
EPS (Forward)-1.56
52W Range
26.5460% of range28.76
52W High28.76 USD
52W Low26.54 USD
Profitability
Gross Margin100.00%
Oper. Margin-1752.61%
EBITDA Margin0.00%
Profit Margin-905.74%
ROE-29.82%
ROA-26.49%
Growth
Revenue Growth-80.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-147.78M $
CapEx (TTM)246.00K $
FCF Margin-636.97%
FCF Yield-1.36%
Net Debt-633.77M $
Net Debt/EBITDA2.60
Balance Sheet
Debt/Equity0.00
Current Ratio9.03
Quick Ratio8.76
Book Value/Sh5.367 USD
Cash/Share5.303 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)52.04 USD
Upside (mean)+86.7%
Target Range38.50 USD – 60.79 USD
$38.50+86.7% to mean$60.79
# Analysts15
Ownership
Shares Out.119.54M
Float82.90M
Insiders0.89%
Institutions106.15%
Short Interest
Short Ratio10.5d
Short % Float9.93%
Short % Out.8.47%
Shares Short9.96M
Short (prev mo.)9.09M
Technical
SMA 5030.61 (-8.9%)
SMA 20033.19 (-16.0%)
Beta0.11
S&P 52W Chg18.16%
Avg Vol (30d)786.77K
Avg Vol (10d)1.12M
Technical Indicators
RSI (14)44.2
MACD-0.9005
MACD Signal-1.1209
MACD Hist.+0.2204
BB Upper29.27 USD
BB Middle27.79 USD
BB Lower26.32 USD
BB Width10.62%
ATR (14)1.355 USD
Vol Ratio (20d)0.47x